Skip to main content
. 2023 Nov 19;4(12):100607. doi: 10.1016/j.jtocrr.2023.100607

Figure 2.

Figure 2

(A) Overall survival from the time of osimertinib initiation by Kaplan-Meier, and (B) cumulative incidence of CNS progression after start of osimertinib considering death as a competing risk. (C) Cumulative incidence of lesion-level local failure after the start of osimertinib considering death as a competing risk. CNS, central nervous system.